BIOMARIN PHARMACEUTICAL INC (BMRN) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Feb 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for BIOMARIN PHARMACEUTICAL INC?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, BIOMARIN PHARMACEUTICAL INC's filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-10.34%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does BIOMARIN PHARMACEUTICAL INC actually do?
Answer:
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing treatments for rare genetic diseases. Founded in 1997 and headquartered in San Rafael, California, the company has eight commercial therapies and a robust pipeline. BioMarin leverages a distinctive approach to drug discovery, aiming to create category-defining medicines that significantly impact patients' lives. In 2025, the company achieved $3.2 billion in total revenues, driven by the expansion of VOXZOGO and growth in its commercial business. BioMarin is actively pursuing strategic growth through internal research, partnerships, and acquisitions, notably announcing a definitive agreement to acquire Amicus Therapeutics in December 2025.
Question:
What are BIOMARIN PHARMACEUTICAL INC's revenue drivers?
Answer:
Revenue is primarily driven by sales of its commercial products, including VOXZOGO, PALYNZIQ, VIMIZIM, NAGLAZYME, ALDURAZYME, and BRINEURA. Sales volume and geographic expansion are key drivers for revenue growth.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required